CANCER DEBT RELIEF

Financially Helping Patients

Home
Donations
Services
Plans Of The Future
Products
Contact Us
Legal Stuff
Help Wanted
Family Colors
Patients
About CDR
Cancer Information
Women
Men
Site Map

 Possible signs of breast cancer.

 

  • a persistent lump or thinkening in the breast or armpit area

 

  • changes in the colour or skin of the breast, areola or nipple(i.e. dimpling, puckering, or scaling)

 

  • a newly retracted/inverted (pulled in) nipple

 

  • blood or discharge from the nipple

 

  • a change in the size or shape of the breast

Paget’s disease of the nipple

 

What are the symptoms?                        

1. A persistent redness, oozing, and crusting of your nipple causing it to itch and burn


2. A sore on your nipple that will not heal.


3. Usually only one nipple is effected. How is it diagnosed? Your doctor will do a physical exam and should suggest having a mammogram of both breasts, done immediately. Even though the redness, oozing and crusting closely resemble dermatitis (inflammation of the skin), your doctor should suspect cancer if the sore is only on one breast. Your doctor should order a biopsy of your sore to confirm what is going on. 

If this had been diagnosed as breast cancer in the beginning, perhaps it would not have spread..

What is Paget’s disease of the nipple?

Paget’s disease of the nipple, also called Paget’s disease of the breast, is an uncommon type of cancer that forms in or around the nipple (1, 2, 3). More than 95 percent of people with Paget’s disease of the nipple also have underlying breast cancer; however, Paget’s disease of the nipple accounts for less than 5 percent of all breast cancers (1). For instance, of the 211,240 new cases of breast cancer projected to be diagnosed in 2005, fewer than 11,000 will also involve Paget’s disease of the nipple (4).

Most patients diagnosed with Paget’s disease of the nipple are over age 50, but rare cases have been diagnosed in patients in their 20s (1). The average age at diagnosis is 62 for women and 69 for men. The disease is rare among both women and men.

Paget’s disease of the nipple was named after Sir James Paget, a scientist who noted an association between changes in the appearance of the nipple and underlying breast cancer (1, 5). There are several other unrelated diseases named after Paget, including Paget’s disease of the bone and Paget’s disease of the vulva; this fact sheet discusses only Paget’s disease of the nipple.


What are the possible causes of Paget’s disease of the nipple?

Scientists do not know exactly what causes Paget’s disease of the nipple, but two major theories have been suggested for how it develops (1, 2). One theory proposes that cancer cells, called Paget cells, break off from a tumor inside the breast and move through the milk ducts to the surface of the nipple, resulting in Paget’s disease of the nipple. This theory is supported by the fact that more than 97 percent of patients with Paget’s disease also have underlying invasive breast cancer or ductal carcinoma in situ (DCIS) (1). DCIS, also called intraductal carcinoma, is a condition in which abnormal cells are present only in the lining of the milk ducts in the breast, and have not invaded surrounding tissue or spread to the lymph nodes. DCIS sometimes becomes invasive breast cancer. Invasive breast cancer is cancer that has spread outside the duct into the breast tissue, and possibly into the lymph nodes under the arm or into other parts of the body.

The other theory suggests that skin cells of the nipple spontaneously become Paget cells. This theory is supported by the rare cases of Paget’s disease in which there is no underlying breast cancer, and the cases in which the underlying breast cancer is found to be a separate tumor from the Paget’s disease (1).


What are the symptoms of Paget’s disease of the nipple?

Symptoms of early Paget’s disease of the nipple include redness and mild scaling and flaking of the nipple skin (1). Early symptoms may cause only mild irritation and may not be enough to prompt a visit to the doctor (3). Improvement in the skin can occur spontaneously, but this should not be taken as a sign that the disease has disappeared. More advanced disease may show more serious destruction of the skin (1). At this stage, the symptoms may include tingling, itching, increased sensitivity, burning, and pain. There may also be discharge from the nipple, and the nipple can appear flattened against the breast (1, 2).

In approximately half of patients with Paget’s disease of the nipple, a lump or mass in the breast can be felt during physical examination (1). In most cases, Paget’s disease of the nipple is initially confined to the nipple, later spreading to the areola or other regions of the breast (1, 2). The areola is the circular area of darker skin that surrounds the nipple. Paget’s disease of the nipple can also be found only on the areola, where it may resemble eczema, a noncancerous itchy red rash (1). Although rare, Paget’s disease of the nipple can occur in both breasts (2).


How is Paget’s disease of the nipple diagnosed?

If a health care provider suspects Paget’s disease of the nipple, a biopsy of the nipple skin is performed (1, 2, 3). In a biopsy, the doctor removes a small sample of tissue. A pathologist examines the tissue under a microscope to see if Paget cells are present. The pathologist may use a technique called immunohistochemistry (staining tissues to identify specific cells) to differentiate Paget cells from other cell types (1). A sample of nipple discharge may also be examined under a microscope for the presence of Paget cells (3).

Because most people with Paget’s disease of the nipple also have underlying breast cancer, physical examination and mammography (x-ray of the breast) are used to make a complete diagnosis.


How is Paget’s disease of the nipple treated?

Surgery is the most common treatment for Paget’s disease of the nipple (1, 2, 5). The specific treatment often depends on the characteristics of the underlying breast cancer.

A modified radical mastectomy may be recommended when invasive cancer or extensive DCIS has been diagnosed (5). In this operation, the surgeon removes the breast, the lining over the chest muscles, and some of the lymph nodes under the arm. In cases where underlying breast cancer is not invasive, the surgeon may perform a simple mastectomy to remove only the breast and the lining over the chest muscles (2, 5).

Alternatively, patients whose disease is confined to the nipple and the surrounding area may undergo breast-conserving surgery or lumpectomy followed by radiation therapy (1, 2, 5). During breast-conserving surgery, the surgeon removes the nipple, areola, and the entire portion of the breast believed to contain the cancer. In most cases, radiation therapy is also used to help prevent recurrence (return of the cancer).

During surgery, particularly modified radical mastectomy, the doctor may perform an axillary node dissection to remove the lymph nodes under the arm (1, 5). The lymph nodes are then examined to see if the cancer has spread to them. In some cases, a sentinel lymph node biopsy may be performed to remove only one or a few lymph nodes.

 

(For more information about sentinel lymph node biopsies, please see National Cancer Institute Fact Sheet 7.44, Sentinel Lymph Node Biopsy: Questions and Answers, at http://www.cancer.gov/cancertopics/factsheet/Therapy/sentinel-node-biopsy on the Internet.)

Adjuvant treatment (treatment that is given in addition to surgery to prevent the cancer from coming back) may be part of the treatment plan, depending on the type of cancer and whether cancer cells have spread to the lymph nodes. Radiation treatment is a common adjuvant therapy for Paget’s disease of the nipple following breast-conserving surgery. Adjuvant treatment with anticancer drugs or hormone therapies may also be recommended, depending on the extent of the disease and prognostic factors (estimated chance of recovery from the disease or chance that the disease will recur).

 

 

New Vaccine Fights Breast Cancer Tumors

DNA Vaccination Kills Herceptin-Resistant Breast Tumors
By Daniel J. DeNoon
WebMD Health News
Reviewed by Louise Chang, MD

Sept. 15, 2008 -- An experimental breast cancer vaccine makes mice reject tumors -- even cancers no longer sensitive to Herceptin.
The vaccine targets breast cancers that grow wildly in response to a growth factor called HER-2. About 25% of women with breast cancer have HER-2 positive tumors.
Herceptin, a man-made antibody approved for the treatment of breast cancer, targets these cancers. But after a while, tumor cells often become resistant to Herceptin.
The new vaccine elicits immune responses that kill HER-2 positive breast tumors in mice, whether or not they've become Herceptin resistant, says Wei-Zen Wei, PhD, professor of immunology at Detroit's Karmanos Cancer Institute.
"Regardless of whether tumor cells are resistant, if immune cells are properly primed by immunization we can destroy these cells," Wei tells WebMD.
The vaccine developed by Wei's team uses DNA that carries the genetic code for a key piece of the HER-2 molecule. After injection of the DNA into the skin, a small electric pulse is administered to help cells take up the DNA and produce the protein that elicits immune responses.
Mice given the vaccine made anti-HER-2 antibodies. The vaccine also primed cellular immune responses that attacked breast cancer tumors. These cellular responses alone were enough to kill HER-2 positive cells in mice unable to make antibodies.
A version of the vaccine is now undergoing human safety tests.
Last April, a different HER-2 vaccine made headlines when it halved the number of deaths in women with HER-2 positive breast cancer. The vaccine also slowed breast cancer recurrence.
However, researchers at San Antonio's Brooke Army Medical Center found that 26 months after vaccination, there was no significant difference in cancer recurrence between vaccinated and unvaccinated women.
Gary Yang, MD, associate professor of radiation medicine at Roswell Park Cancer Institute in Buffalo, N.Y., says these human studies are a major step forward.
"These studies accomplished a lot -- but we need to find out why the immune system cannot sustain this efficacy," Yang tells WebMD.
Yang says that is why Wei's team's work is so important. What's learned in the lab must be tested in patients -- and then more lab work is needed to answer questions raised by human studies.
"The clinical research into breast cancer vaccines is not going to be a home run," he says.
Wei is convinced that in the long run, vaccines will prove to be powerful cancer treatments.
"Ultimately, we will be using the best defense we have to fight cancer -- the human immune system," she says. "It is a very challenging thing to do. We hope we have reached a point where we can make it useful to patients."
Wei and colleagues report their findings in the Sept. 15 issue of Cancer Research.